BGPT: Paper Review: Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides

Explore by Goal

Quick Explanation Copied

Rigorous take on the PARG inhibitor medicinal chemistry

The paper reports structure-guided scaffold hopping from an anthraquinone PARG hit (8a) to quinazolinedione sulfonamides, using enzyme/cell potency, selectivity vs PARP1 and ARH3, crystallography, and early PK in mice. Key reported biochemical and cell gains come with an explicit hydrogen-bonding “sulfonamide pharmacophore” and a steep SAR by N-alkyl and N3 heteroaryl choices ().

Long Explanation

Paper Review (Visual-first): PARG inhibitors via quinazolinedione sulfonamides

DOI: 10.1021/acs.jmedchem.8b01407 • Publication: Nov 7, 2018 ()

What the authors set out to do

The core motivation is that PARG inhibition is therapeutically interesting for DNA damage response biology, but prior small-molecule inhibitors were limited by druggability/selectivity and poor cell-permeability, motivating the discovery of potent, cell-active and orally bioavailable PARG inhibitors ().

Data at-a-glance (from paper tables)

The paper reports an initial N-alkyl sulfonamide SAR around anthraquinone hit 8a and then successive quinazolinedione optimization, with explicit enzyme EC50 and cell EC50 measurements reported as geometric means with standard deviations, and additional physicochemical and selectivity profiling ().

Figure 1 — Hit 8a and initial sulfonamide N-alkyl SAR

Biochemical PARG EC50 vs cellular PARG-chain persistence EC50 for compounds explicitly listed in Table 1 ().

Figure 2 — Representative physicochemical/cytotoxicity comparison (Table 4 excerpt)

The paper compares measured properties and cytotoxicity for representative compounds including 8a and 12b ().

Key mechanistic narrative (what’s well-supported vs inferred)

1) Binding mode & pharmacophore

The paper crystallizes the anthraquinone 8a with the human PARG catalytic domain and reports direct binding in the PAR (ADP-ribose) site region, with a sulfonamide hydrogen-bonding network to Glu727, Ile726 backbone NH, and Gln754 backbone NH, plus aromatic stacking involving residues such as Phe902 and Tyr795 ().

2) Steep SAR and “vector logic” for quinazolinedione optimization

The authors describe that sulfonamide N-alkyl substitution is steep for activity, and they exploit a scaffold hop to quinazolinedione sulfonamides while retaining the sulfonamide pharmacophore. They then treat N1 and N3 substitution as separate “vectors” with distinct SAR, with crystallography supporting predicted binding poses for key intermediates (e.g., 22h and 27t) and revealing hydrogen-bond contributions (e.g., involving Asn869 for specific heterocycles) ().

3) Potency, selectivity, and early in vivo PK

The paper reports that combining optimized N1 and N3 substituents leads to biochemical EC50 down to low nanomolar levels for at least one compound (34f) and that cellular proof-of-mechanism PAR chain persistence aligns with biochemical potency. It also reports selectivity against PARP1 and ARH3 by measuring activity in those assays, and includes preliminary PK for selected oxetan-3-ylmethyl derivatives (33d/35d) in male CD-1 mice with additional descriptors like IV clearance and oral bioavailability flags ().

Figure 3 — Example in vitro PK-related parameters for 33d vs 35d (Table 10 excerpt)

The paper’s excerpted Table 10 lists IV AUC, T1/2, Vd, IV clearance, and oral F (%) for 33d and 35d ().

Critical evaluation (skeptical, evidence-anchored)

What looks strong

The paper uses crystallography to directly support a binding-site pharmacophore concept (sulfonamide hydrogen bonds) and then uses those structural observations to guide scaffold hopping and SAR “vector” choices for quinazolinedione N1/N3 substitutions ().
The enzymatic biochemical readout and cellular proof-of-mechanism readout are both presented, and the authors explicitly position the cellular PAR-chain persistence assay as aligned with biochemical EC50 for optimized compounds ().
Selectivity against at least PARP1 and ARH3 is reported via EC50 measurements in relevant assays, providing evidence that the best cellular potency compounds are not simply broad-spectrum PAR-system inhibitors ().

Potential blind spots / limitations (and why they matter)

Assay-dependent potency interpretation: The paper’s early potency decisions are heavily dependent on docking + HTRF biochemical EC50 + cellular PAR-chain persistence readout. While that is standard, a skeptical view is that cell assays can be confounded by permeability/efflux and by off-target DNA-binding or cytotoxic motifs—issues the authors themselves discuss for the earlier anthraquinone series ().
“Selectivity” scope limitation: The paper reports PARP1 and ARH3 selectivity thresholds, but that does not automatically rule out other off-target PARP-family members or unrelated enzymes; absence-of-evidence outside the tested panel is a known limitation of target-selectivity claims. This is not a criticism of missing experiments per se—just a boundary on interpretability ().
In vivo translation is preliminary: The paper provides preliminary mouse PK for selected derivatives and positions oral bioavailability as moderate, but the excerpted PK data also describe rapid clearance and mouse-only, single-dose-type profiling. Without an expanded PK/PD and efficacy package, “orally bioavailable” is best interpreted as pharmacokinetically feasible—not as proven therapeutic efficacy ().

Missing-information checks (what I cannot verify from the provided full text)

I cannot extract a full dataset of every compound’s EC50/LE/LLE/microsomal stability values from the provided excerpt alone (tables beyond the visible snippets are not fully present here). Therefore, I can’t rigorously compute global correlations (e.g., logP vs potency vs cytotoxicity) across the entire library from this message content.
I cannot verify whether all optimized compounds were benchmarked against a broader enzymatic panel or whether extensive chemical proteomics/off-target profiling was done, because only PARP1/ARH3 selectivity is visible in the provided excerpt.

Most important takeaways (skeptical & actionable)

Sulfonamide H-bonding is treated as the pharmacophore anchor, and the paper uses that as a conserved element across scaffold hops from anthraquinone to quinazolinedione ().
N1 vs N3 positions behave as different SAR “degrees of freedom”, with N3 heteroaryl positioning able to introduce a key hydrogen bond to Asn869, and with regioisomer effects described as large ().
Cell toxicity is a key design constraint that the authors explicitly report as problematic for the anthraquinone series, and they claim the quinazolinediones largely avoid that nonmechanistic toxicity ().

Author review links (click to go deeper)

Feedback:

Updated: July 10, 2026